AQST vs. ACIU, PBYI, ME, VSTM, IMMP, TSVT, ALDX, PYXS, XBIT, and XERS
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include AC Immune (ACIU), Puma Biotechnology (PBYI), 23andMe (ME), Verastem (VSTM), Immutep (IMMP), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), Pyxis Oncology (PYXS), XBiotech (XBIT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical preparations" industry.
Aquestive Therapeutics (NASDAQ:AQST) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.
AC Immune has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -15.56%. Aquestive Therapeutics' return on equity of 0.00% beat AC Immune's return on equity.
AC Immune received 58 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. However, 66.33% of users gave Aquestive Therapeutics an outperform vote while only 62.16% of users gave AC Immune an outperform vote.
Aquestive Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 159.32%. AC Immune has a consensus target price of $16.00, suggesting a potential upside of 580.85%. Given AC Immune's higher probable upside, analysts plainly believe AC Immune is more favorable than Aquestive Therapeutics.
In the previous week, Aquestive Therapeutics had 6 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.05 beat Aquestive Therapeutics' score of -0.31 indicating that AC Immune is being referred to more favorably in the news media.
Aquestive Therapeutics has higher revenue and earnings than AC Immune. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Aquestive Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Summary
Aquestive Therapeutics beats AC Immune on 10 of the 17 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
